-
white matter. The network aims to strengthen the full translational pathway, from understanding disease mechanisms and developing disease models to preclinical therapy testing, clinical readiness and
-
white matter. The network aims to strengthen the full translational pathway, from understanding disease mechanisms and developing disease models to preclinical therapy testing, clinical readiness and
-
the brain white matter. The network aims to strengthen the full translational pathway from disease mechanism and model development to preclinical therapy testing, clinical readiness and patient-informed
-
white matter. The network aims to strengthen the full translational pathway, from understanding disease mechanisms and developing disease models to preclinical therapy testing, clinical readiness and
-
mechanisms and developing disease models to preclinical therapy testing, clinical readiness and patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy
-
white matter. The network aims to strengthen the full translational pathway from disease mechanisms and model development to preclinical therapy testing, clinical readiness and patient-informed treatment
-
the brain white matter. The network aims to strengthen the full translational pathway from disease mechanism and model development to preclinical therapy testing, clinical readiness and patient-informed
-
white matter. The network aims to strengthen the full translational pathway, from understanding disease mechanisms and developing disease models to preclinical therapy testing, clinical readiness and
-
white matter. The network aims to strengthen the full translational pathway, from understanding disease mechanisms and developing disease models to preclinical therapy testing, clinical readiness and
-
mechanisms and model development to preclinical therapy testing, clinical readiness and patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology